Rubicon Research Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RUBICON RESEARCH
RUBICON RESEARCH has seventy-five approved drugs.
Summary for Rubicon Research
| US Patents: | 0 |
| Tradenames: | 61 |
| Ingredients: | 60 |
| NDAs: | 75 |
Drugs and US Patents for Rubicon Research
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rubicon Research | GUANFACINE HYDROCHLORIDE | guanfacine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 219689-003 | Apr 15, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Rubicon Research | CLONAZEPAM | clonazepam | TABLET;ORAL | 075468-003 | Oct 6, 2000 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Rubicon Research | LOPERAMIDE HYDROCHLORIDE | loperamide hydrochloride | CAPSULE;ORAL | 216876-001 | Jan 26, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Rubicon Research | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204028-001 | Jun 29, 2015 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Rubicon Research | TIZANIDINE HYDROCHLORIDE | tizanidine hydrochloride | CAPSULE;ORAL | 213798-001 | May 27, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
